The profiles of an i.v. bolus and 3 h and 20 h infusion of cisplatin (CDDP) were simulated in vitro by using a culture of the IGROVI human ovarian cancer cell line. Disappearance of pharmacologically active unbound CDDP was accomplished by adding human albumin to the medium. Total and unbound CDDP and CDDP-DNA adduct levels were quantitated by atomic absorption spectroscopy (AAS), and tumour cell survival was measured by the clonogenic assay. The design of the experiment resulted in non-significant differences in the magnitude of the area under the concentration-time curve (AUC) of unbound CDDP between the three dose-input functions (AUC i.v. bolus, 6.34 ± 0.36; 3 h infusion, 6.35 ± 0.59; and 20 h infusion, 6.76 ± 0.40 pg h ml-'). Also, the differences between the area under the CDDP-DNA adduct -time curves (AUA) of the three dose-input functions were not significant. The initial rate of decline of the CDDP-DNA adduct-time curve was significantly higher for the i.v. bolus and 3 h infusion than for the 20 h infusion. There was a log-linear relationship between the AUC of unbound CDDP and cell survival. These relationships were not significantly different between the three dose-input functions. Variation in the rate of input of CDDP leads to differences in the shape of the AUC and AUA without significant effects on cell survival.
CDDP is one of the most potent cytotoxic compounds in vivo and is used frequently for the treatment of ovarian and testicular cancer, head and neck cancer and other malignancies (Loehrer & Einhorn, 1984; Forastiere et al., 1987; Reed et al., 1988a; 1990) . Its application is accompanied by doselimiting side-effects, such as nephro-, neuro-and ototoxicity (Kovacs et al., 1982; Meijer et al., 1983; Vermorken et al., 1983) . Despite its long-standing and wide clinical application, the optimal schedule of CDDP, with a maximal attainable anti-tumour effect and tolerable side-effects, has never been clearly established. From early studies it became evident that a rapid i.v. infusion was associated with the development of profound, and sometimes irreversible, nephrotoxicity. Because of this infusion times were prolonged, with intensive pre-and post-hydration and administration of CDDP in saline solutions (Jacobs et al., 1978; Salem et al., 1984; Vogelzang, 1984) , rendering side-effects more manageable. The influence of the variation of the rate of input (i.e. dose-input function per treatment cycle) on the cytotoxic activity of CDDP is less clearly defined. Clinical observations suggest that the anti-tumour effect is not influenced by the dose-input function (Vermorken et al., 1982) .
Data on the pharmacokinetic-dynamic relationships of CDDP in clinical and preclinical studies, taking the CDDP-DNA adduct formation and repair and exposure to unbound CDDP into consideration, are lacking.
CDDP binds almost irreversibly to plasma and cellular components (Yotsuyanagi et al., 1991) . This results in an extremely long retention of CDDP in tissues (Loehrer & Einhorn, 1984) . The elimination half-life of the pharmacologically active unbound CDDP in the plasma is short and is approximately 1 h in man (Vermorken et al., 1982 (Vermorken et al., , 1986 . The cytotoxic activity of CDDP is very likely correlated to the covalent binding to DNA, so-called inter-and intrastrand adduct formation (Plooy et al., 1984) . This is not an irreversible process because of the cellular capacity to remove the formed adducts (DNA repair) (Plooy et al., 1984; Fichtinger-Schepman et al., 1987 Assay of CDDP in the culture medium Total and unbound CDDP were analysed by AAS. One millilitre of medium was taken for the analysis of the total and unbound CDDP concentration. For the total CDDP concentration, 100lI was taken and diluted 10-40 times with 0.2% Triton X-100 containing 0.06% caesium chloride in order to obtain CDDP concentrations in the range 10-100 ng ml'. Unbound CDDP was analysed after deproteination of 0.5 ml of the medium sample with 1.0 ml of ice-cold absolute ethanol. A volume of 250 jAI was taken and diluted 10-40 times with deionised water. A volume of 50 tll was injected into the AAS. All measurements were carried out in duplicate.
Assay of DNA levels in tumour cells DNA levels in tumour cells were determined according to a method described by Fichtinger-Schepman et al. (1987) .
Analysis of CDDP-DNA adduct levels CDDP-DNA adduct levels were quantitated according to a method described by Reed et al. (1988b) with modifications. Briefly, a DNA sample was digested with DNAse I and zinc chloride (10 iM, 10 .l) was added to the mixture to optimise the enzymatic reaction (Fichtinger-Schepman et al., 1987) . A volume of 160 .l (approximately 60-250 lg of DNA) was injected into the furnace using the 4 x multiple sampling feature of the instrument. The samples were calibrated on a standard curve of four samples with a Pt concentration of 0, 1.5, 3, 6 ng ml-1' (equivalent to 0, 240, 480, 960 pg of Pt in the injected volume of 160fd). CDDP-DNA adduct levels were expressed as pg of Pt per tLg of DNA (pg Pt pg 'DNA).
The analysis was carried out in duplicate.
CDDP-protein binding experiment CDDP (10 tLg ml-') was incubated for 24 h at 37°C with human plasma (15 ml) and a 7% (v/v) human albumin solution in RPMI-1640, containing 10% BCS (total volume of the mixture, 15 ml). During the incubation period total and unbound CDDP were analysed at 0, 0. 44 and 68 h from the start a flask was used to harvest cells for measurement of the CDDP-DNA adduct level. During the incubation 1 ml of medium was taken at 0, 0.5, 1, 2 and 3 h for measurement of the concentration of total and unbound CDDP.
Three hour infusion profile Every 15min for lh a small, but constant, amount of CDDP (18.41 l containing 0.2 mg ml-' CDDP) was added to the 16 ml of culture medium. After another 1l h of incubation 8 ml of 20% albumin was added to the flask immediately followed by CDDP (51.2 1Al of a solution of 0.2mg ml' CDDP), to prevent dilution of CDDP in the flask owing to the addition of the relatively large volume of albumin solution. Five hours later (8 h from the start) the medium was removed and the cells were washed and cultured again as outlined. The same CDDP-DNA adduct time points were determined as in the i.v. bolus experiment. During the incubation 1 ml of medium was taken at 0, 0.5, 1, 2, 3 and 8 h for measurement of the total and unbound CDDP concentration.
Twenty-hour infusion profile Seven flasks were used. CDDP was added at time point 0 h, and after 20 h the medium was removed. Subsequently, the cells were washed and cultured as outlined. The CDDP-DNA adduct time points were 1, 3, 8, 20, 24, 44 (Figure 1) . After 1 h approximately 50% of CDDP was bound in both experiments. After 24 h only 3% was unbound.
In the protein-free medium there was a linear increase in adduct formation with time ( Figure 2) . Addition of albumin, immediately followed by CDDP, resulted in a significantly lower increase in adducts with time. When CDDP was preincubated with albumin, thereby eliminating unbound CDDP, no significant adduct formation was observed.
Assay of CDDP in the culture medium Total and unbound CDDP could be analysed reproducibly in the observed concentration range 0.1-5 fig ml-'. Coefficients of variation were <5%. The measured concentration-time curves of total and unbound CDDP in the three experiments are given in Figure 3 . The profiles of unbound CDDP in the simulated i.v. bolus and 3 h and 20 h infusions were not significantly different from those expected in plasma. The elimination half-life of unbound CDDP in the i.v. bolus experiment was 1.5 ± 0.20 h, and in the 3 h infusion experiment 1.7 ± 0.20 h (not significantly different). In the i.v. bolus experiment only 22% of CDDP was unbound after 3 h of incubation. In the 20 h infusion experiment 55% was unbound after 20 h of incubation (Figure 3) . The Cmax of CDDP was highest in the i.v. bolus and lowest in the 20 h infusion experiment (Table I ). The AUC values of the three dose-input functions were not significantly different.
Analysis of DNA and CDDP-DNA adduct levels CDDP-DNA adduct levels could be determined reproducibly in the observed range 0.5-15 pg Pt jig`D NA. The coefficient of variation was 20% at 1.5ngml-'Pt (240pg of Pt per injected sample) and 8% at higher concentrations. The detection limit was 100 pg of Pt per sample.
The maximal adduct levels (Amax) were reached at the end of the incubation with CDDP (Figure 4 ). The differences between the three experiments were not significant (Table I) , although there appeared to be a rank order, with the i.v. bolus having the highest and the 20 h infusion experiment the lowest Amax level. Also, the AUA values, calculated up to 68 h, were not significantly different between the experiments. The initial decline in the adduct-time curve (initial slope in Table I ) was significantly more rapid in the i.v. bolus and 3 h infusion than in the 20 h infusion experiment.
Cell survival measurement The decline in cell survival with time was highest in the i.v. bolus and lowest in the 20 h infusion experiment ( Figure 5) . A log-linear relationship was observed between the decline in the cell survival and the AUC of unbound CDDP (Figure 6 ). The slopes of the three dose-input functions were not significantly different (Figure 6 ). The log-linear slope of the i.v. bolus experiment was 12.9 ± 0.13, of the 3 h experiment 13.2 ± 0.66 and of the 20 h experiment 11.7 ± 0.53 (all n = 3; not significantly different). 
Discussion
In the present study relationships were established between the exposure to unbound CDDP, CDDP-DNA adduct kinetics and tumour cell survival. To assess these relationships former and presently used clinical dose-input functions were simulated in vitro, using a cell culture of the IGROVI human ovarian cancer cell line. After administration to patients, unbound CDDP is eliminated by irreversible protein binding and renal elimination. The clearance by protein binding exceeds renal clearance of unbound CDDP by a factor of approximately 4-5 (Bajorin et al., 1986) . Irreversible protein binding can easily be simulated in vitro, as is illustrated in Figure 1 . Human albumin was added to the RPMI-1640 culture medium of the IGROVI cell line as outlined. The results show that the protein binding kinetics in this mixture and in human plasma are similar. The concentration range of CDDP in vitro in the present study was of the same order as is observed in plasma of patients after administration of a dose of approximately 80 mg m-2 (Vermorken et al., 1986) . The elimination kinetics of CDDP in vitro, using the outlined approach, reflects the kinetics in vivo (Vermorken et al., 1982 (Vermorken et al., , 1986 . The elimination half-life is slightly longer because of the absence of renal clearance. In the present model the remaining low concentration of unbound CDDP was removed from the medium after 3, 8 Protein-bound CDDP is not able to form CDDP-DNA adducts, which is illustrated in Figure 2 . Hence unbound CDDP should be used for the assessment of the pharmacokinetic-dynamic relationship. In the light of this observation it should be realised that clinical trails which use CDDP preincubated with albumin (Holding et al., 1992) may not lead to significant anti-tumour responses. The design of the simulation of the three dose-input functions resulted in non-significant differences in the AUC of unbound CDDP. This is an ideal starting point to assess the influence of the rate of input of CDDP on CDDP-DNA adduct formation and repair and cell survival.
The Am.x in the three experiments was not significantly different, although the level in the i.v. bolus and 3 h infusion was slightly higher than in the 20 h infusion. The AUA was clearly not significantly different in the three dose-input functions. This illustrates that the rate of input of CDDP does not influence the magnitude of the adduct formation.
The initial rate of decline of the adduct-time curve was significantly lower in the 20 h infusion. The rate of decline was studied in all experiments after withdrawal of CDDP. It is not clear what mechanism caused the difference. Furthermore, the increase in the adduct formation with time in the 20 h infusion experiment is clearly non-linear (Figure 4) . However, the experimental design does not permit assessment of differences in adduct removal during the period of CDDP exposure. The observed differences in the adduct kinetics had no implications for cell survival ( Figure 6 ). This seems to be in contrast to the results of the Troger et al. (1992) . They found that the longest exposure time of total CDDP in a head and neck cancer cell line resulted in the lowest cytotoxicity. However, protein binding of CDDP in the culture medium was not taken into account and no adduct levels were determined. Correction for the unavoidable protein binding of CDDP might have changed the results of that study.
The log-linear relationship between the AUC of unbound CDDP and cell survival was strikingly similar in the three dose-input functions. This implies that cell kill is determined not by the rate of input of CDDP, but by the magnitude of the exposure to unbound CDDP. If these results are confirmed in other tumour models, then they may have significant implications in designing optimal modes of clinical CDDP administration.
